These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36621167)

  • 1. Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways.
    Kong Q; Ma M; Zhang L; Liu S; He S; Wu J; Liu B; Dong J
    Phytomedicine; 2023 Feb; 110():154638. PubMed ID: 36621167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
    Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
    J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
    Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
    J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice.
    Feng XY; Chen BC; Li JC; Li JM; Li HM; Chen XQ; Liu D; Li RT
    Phytomedicine; 2021 Dec; 93():153779. PubMed ID: 34638030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
    Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
    Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
    Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
    Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects.
    Li M; Xie Y; Zhang J; Zhou X; Gao L; He M; Liu X; Miao X; Liu Y; Cao R; Jia Y; Zeng Z; Liu L
    Cancer Lett; 2024 Aug; 598():217111. PubMed ID: 38972347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer.
    Xun J; Jiang X; Liu B; Hu Z; Liu J; Han Y; Gao R; Zhang H; Yang S; Yu X; Wang X; Yan C; Zhang Q
    Int Immunopharmacol; 2024 Sep; 139():112696. PubMed ID: 39018692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
    Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
    Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer.
    Liu D; You M; Xu Y; Li F; Zhang D; Li X; Hou Y
    Int Immunopharmacol; 2016 Oct; 39():265-272. PubMed ID: 27497194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications.
    Tong X; Qiao S; Dong Z; Zhao X; Du X; Niu W
    J Nanobiotechnology; 2024 Jul; 22(1):409. PubMed ID: 38992688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells.
    Lin S; Zhang X; Huang G; Cheng L; Lv J; Zheng D; Lin S; Wang S; Wu Q; Long Y; Li B; Wei W; Liu P; Pei D; Li Y; Wen Z; Cui S; Li P; Sun X; Wu Y; Yao Y
    Oncogene; 2021 Feb; 40(8):1476-1489. PubMed ID: 33452453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.